Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 849 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Prospective Blood Draw Clear all

Conditions: Bladder Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Crohn's Disease
Interventions: Infliximab, Placebo; Biological · Drug
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 62
States / cities: Birmingham, Alabama • La Jolla, California • Orange, California + 59 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Observational study; Other
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 3 Years to 18 Years · Male only
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Sacramento, California • Cincinnati, Ohio • Columbus, Ohio

Conditions: Neuroblastoma, Sarcoma, Pediatric Cancer
Interventions: 13C-glucose, No glucose infusion; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Up to 26 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Eosinophilia, Hypereosinophilic Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Year to 100 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: SARS CoV 2 Infection, Respiratory Syncytial Virus (RSV), Bronchiolitis, Asthma
Interventions: Not listed
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2028
U.S. locations: 2
States / cities: Metairie, Louisiana • New Orleans, Louisiana

Conditions: Sarcoma
Interventions: Non-Metastatic and Resectable, Metastatic and Un-resectable, No evidence of disease, under surveillance, ALT or WDLS; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina

Conditions: Highly Sensitized Prospective Kidney Transplant Recipients
Interventions: carfilzomib, belatacept, Bone marrow aspiration; Biological · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hematopoietic Cell Transplantation
Interventions: Biorepository Trial; Other
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 26 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 3
States / cities: Rochester, Minnesota • Durham, North Carolina • Houston, Texas

Conditions: Craniectomy, Trephined Syndrome, Traumatic Brain Injury (TBI) Patients, Ischemic Stroke
Interventions: External Cranial Prosthesis; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Hematologic Disease, Blood Coagulation Disorders
Interventions: Recombinant Factor VIII (Kogenate, BAY 14-2222); Behavioral
Lead sponsor: Bayer; Industry
Eligibility: 14 Years to 29 Years · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 7
States / cities: Duarte, California • Denver, Colorado • Peoria, Illinois + 4 more

Conditions: Hypertension
Interventions: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter, Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Drug
Lead sponsor: Novartis; Industry
Eligibility: 55 Years and older
Enrollment: 11,506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Prostate Cancer
Interventions: Staple Ligation, Selective Suture Ligation, Single Suture Ligation; Procedure
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Severe Combined Immunodeficiency, Malignancy, Hematologic, Neuroblastoma, Neoplasm, Mucopolysaccharidosis I
Interventions: Venipuncture; Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Lung Cancer Diagnosis
Interventions: blood draw; Diagnostic Test
Lead sponsor: Freenome Holdings Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 20,000 participants
Timeline: 2023 – 2027
U.S. locations: 36
States / cities: Los Angeles, California • Stamford, Connecticut • DeLand, Florida + 33 more

Conditions: Colorectal Cancer (Diagnosis)
Interventions: Not listed
Lead sponsor: Harbinger Health; Industry
Eligibility: 45 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Cancer, Immune-related Adverse Event
Interventions: Medical chart review; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Blood Loss
Interventions: Bipolar Sealer (Aquamantys), Standard of Care; Device · Procedure
Lead sponsor: Salient Surgical Technologies; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Royal Oak, Michigan

Conditions: Poor Glycemic Control
Interventions: Metformin, Glargine insulin, Glulisine; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Spinal Muscular Atrophy
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Esophageal Stricture, Stricture
Interventions: Purastat SAP gel application; Device
Lead sponsor: AdventHealth; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Orlando, Florida • Fort Wayne, Indiana • Baltimore, Maryland + 3 more

Conditions: Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
Interventions: ABT-335, Simvastatin, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: North Chicago, Illinois

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2023
U.S. locations: 20
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 16 more

Conditions: Vital Sign Evaluation
Interventions: Informed Vital Core App; Device
Lead sponsor: Mindset Medical; Industry
Eligibility: 22 Years to 85 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 6
States / cities: Mobile, Alabama • La Mesa, California • Meridian, Idaho + 3 more

Search by objective public record fields.

Bladder Bank (a Prospective Banking Study)

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.

Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics]

A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

Transplacental Transmission of RSV (TTRSV)

LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy and Spectroscopy-based Molecular Urinalysis in Sarcoma Patients

Carfilzomib and Belatacept for Desensitization

A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).

External Post-Operative Skull Prosthesis to Prevent Sunken Flap Syndrome in Craniectomy Patients

Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A

Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension

Staple vs. Suture in Robotic Prostatectomy

Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

Colorectal Lesion Evaluation and Appropriate Resolution (CLEAR) Study

Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy

Salient Aquamantys Spine Trial

Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients

Prospective Evaluation of Infants With Spinal Muscular Atrophy:

Self-Assembling Matrix Forming Gel to Prevent Stricture Formation

Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer

A Multi-Center Prospective Open Label Study of a Web-based Application for Pulse Rate in Adult Patients